| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 76942 |
|
30,344 |
20,176 |
$902K |
| 64418 |
|
9,457 |
7,396 |
$687K |
| 64450 |
|
18,368 |
11,819 |
$658K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,295 |
14,754 |
$439K |
| G0397 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes |
11,108 |
7,446 |
$241K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,903 |
4,818 |
$218K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
9,527 |
7,031 |
$160K |
| 80305 |
|
22,698 |
16,853 |
$131K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
24,579 |
17,729 |
$118K |
| 93922 |
|
1,875 |
1,138 |
$84K |
| 95924 |
|
1,781 |
1,687 |
$78K |
| 20553 |
|
2,467 |
1,898 |
$67K |
| 99490 |
Ccm add 20min |
9,310 |
8,093 |
$62K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
888 |
841 |
$52K |
| 95923 |
|
1,754 |
1,662 |
$48K |
| 80320 |
|
3,455 |
2,752 |
$23K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
613 |
583 |
$19K |
| 96127 |
|
9,194 |
6,225 |
$17K |
| 93040 |
|
1,714 |
1,630 |
$9K |
| 27096 |
|
89 |
73 |
$9K |
| 95911 |
|
93 |
91 |
$7K |
| 95912 |
|
52 |
47 |
$3K |
| 20552 |
|
73 |
68 |
$2K |
| 95885 |
|
159 |
152 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
58 |
58 |
$1K |
| 95886 |
|
19 |
16 |
$231.52 |
| 99072 |
|
127 |
105 |
$197.00 |
| 94760 |
|
910 |
726 |
$13.15 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
1,487 |
1,087 |
$10.79 |
| G3002 |
Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) |
16 |
16 |
$0.00 |